News
11-17-2013, 10:40 PM
Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.
More... (http://www.news-medical.net/news/20131118/Eisai-partners-with-NewBridge-Pharmaceuticals-to-market-Halaven-drug-in-Middle-East.aspx)
More... (http://www.news-medical.net/news/20131118/Eisai-partners-with-NewBridge-Pharmaceuticals-to-market-Halaven-drug-in-Middle-East.aspx)